A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis

(2020) Rohit Loomba et al.   HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

FXR Agonists as Therapy for Liver Disease

(2020) Jay H. Hoofnagle   HEPATOLOGY

Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing

(2020) Richard Aspinall et al.   JOURNAL OF HEPATOLOGY

Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial

(2020) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

Type 2 diabetes mellitus is a risk factor for progression of liver fibrosis in middle‐aged patients with nonalcoholic fatty liver disease

(2019) Toshifumi Tada et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Molecular tuning of farnesoid X receptor partial agonism

(2019) Daniel Merk et al.   Nature Communications

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States

(2019) Zobair M. Younossi et al.   DIABETES CARE

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Magnetic Resonance vs Transient Elastography Analysis of Patients With Non-alcoholic Fatty Liver Disease: a Systematic Review and Pooled Analysis of Individual Participants

(2018) Cynthia Hsu et al.   Clinical Gastroenterology and Hepatology

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

(2017) Chris Estes et al.   HEPATOLOGY

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Quantification of Hepatic Steatosis With a Multistep Adaptive Fitting MRI Approach: Prospective Validation Against MR Spectroscopy

(2015) Mustafa R. Bashir et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease

(2013) Rajarshi Banerjee et al.   JOURNAL OF HEPATOLOGY

Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging

(2013) Xiaodong Zhong et al.   MAGNETIC RESONANCE IN MEDICINE

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

(2009) Stefano Fiorucci et al.   TRENDS IN PHARMACOLOGICAL SCIENCES